Vigabatrin FAQ

VGB is a common abbreviation for vigabatrin, used in research papers and clinic notes. Vigabatrin is a seizure medicine sold in the US as Sabril, as the ready-to-use liquid Vigafyde, and as generics such as Vigadrone.

The boxed warning is about permanent vision loss. Vigabatrin can narrow side vision in both eyes and may also reduce sharpness of vision. Based on adult studies, 30 percent or more of patients can be affected. The risk rises with dose and total exposure, and no dose is known to be risk-free. Vision is checked before or soon after starting, at least every 3 months during treatment, and about 3 to 6 months after stopping.

The vision loss narrows side vision, and babies cannot do the field tests that adults do, so eye specialists use other methods such as electroretinography. Do not rely on noticing changes yourself. Keep every scheduled eye exam, and tell the doctor about any change you notice in how your baby looks at or follows things.

Yes. Vigafyde, approved by the FDA in June 2024, is a ready-to-use oral solution at 100 mg per mL. It needs no mixing and is kept for up to 90 days after opening. It is labeled only for infantile spasms in babies 1 month to 2 years old.

Empty each 500 mg packet into a clean cup and dissolve it in 10 mL of cold or room-temperature water per packet. That makes 50 mg per mL. Check that it is clear, draw up the prescribed volume with an oral syringe, give it right away and throw away what is left.

The labels say to mix it with water only and use it immediately. A 2025 lab study by a generic maker found the powder stayed within potency limits for 48 hours in the fridge in apple juice, whole milk or infant formula. That is not label guidance, so ask your pharmacist or prescriber before mixing it with anything other than water.

The Vigafyde label allows it to be given by mouth or through a gastrostomy (G) tube. With a GJ tube, use the G-port. Flush the tube with water afterward.

The 500 mg tablet is scored, but no study has measured how evenly vigabatrin tablets split or how much a crushed tablet delivers. Studies of other tablets show hand-splitting is often uneven, and crushing raises exposure to the drug for the person doing it. If a dose cannot be made from whole tablets, ask the prescriber about the powder.

GABA is a chemical messenger that calms nerve activity. Vigabatrin permanently blocks GABA transaminase, the enzyme that breaks GABA down, so GABA levels in the brain rise. Because the enzyme block is irreversible, the effect lasts longer than the drug stays in the blood.

NIOSH lists vigabatrin because of possible harm to pregnancy and development; that is its only flagged hazard. The NIOSH and USP handling rules are written for healthcare workers, not for parents, and do not ask families to wear masks. At home, handle the medicine calmly and cleanly, and ask the pharmacist about handling if someone in the house is pregnant or planning a pregnancy.

In infants, sleepiness and irritability are common. In older children and adults, drowsiness, dizziness, headache and fatigue are common, and weight gain can occur. If sleepiness affects feeding or daily life, tell the prescriber rather than changing the dose yourself. Vision loss is the most serious risk and is checked with regular eye exams.

It can. In the label's pooled pediatric trials, 47 percent of children on vigabatrin gained at least 7 percent of their body weight, against 19 percent on placebo. In a trial against carbamazepine in newly diagnosed epilepsy, weight gain was reported in 11 percent on vigabatrin and 5 percent on carbamazepine.

Often days. In a US national cohort, babies who responded to vigabatrin did so in a median of 3 days, and experts advise reassessing any baby who has not responded within a week. The label advises stopping vigabatrin for infantile spasms if it has not clearly helped within 2 to 4 weeks.

No. Stopping suddenly can bring on seizures. The dose is lowered gradually; in the infantile spasms study it was reduced by 25 to 50 mg/kg every 3 to 4 days. The prescriber sets the plan, and vision is checked again 3 to 6 months after the last dose.

Yes. For infantile spasms caused by TSC, guidelines worldwide recommend vigabatrin as a first-line treatment, and spasms stop in most babies. Starting vigabatrin before seizures appear is still debated: one trial found fewer seizures, another found no benefit for development or focal seizures.

A link between vigabatrin vision loss and low taurine is a hypothesis that has been reviewed in the research literature, but our sources include no study showing that taurine supplements protect vision in people taking vigabatrin. Do not start a supplement without asking the prescriber.

It depends on the product, your insurance and the pharmacy, and list prices change, so we do not publish prices. Vigabatrin is filled only by REMS-certified pharmacies. Ask the pharmacy what you will pay, and ask the pharmacy or the product's manufacturer whether a copay program applies.

Vigadrone is a generic vigabatrin powder for oral solution, approved in 2018. It comes in 500 mg packets and is mixed the same way as Sabril powder. Vigafyde is the only ready-to-use vigabatrin liquid; no generic version of it appears in FDA records.